Condition: Major Depressive Disorder (MDD · Sponsor: Sichuan Purity Pharmaceutical Technology Co., Ltd.
The purpose of this study is to learn about: * To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior * To evaluate the safety and pharmacokinetic (PK) characteristics after multiple dose of PRT-042 nasal spray in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior
This description comes directly from the study's public registry record.
ke yao · 86-028-85170738 · ke.yao@btyy.com
Always discuss trial participation with your own doctor first.
| BEIjing AnDing hospital capital medical university | Beijing, China | Recruiting |
| Beijing AnDing hospital capital medical university | Beijing, China | Recruiting |
| Beijing Huilongguan Hospital | Beijing, China | Recruiting |
| The Fourth People's Hospital of Chengdu | Chengdu, China | Recruiting |
| Hangzhou Seventh People's Hospital | Hangzhou, China | Recruiting |
| The fourth affiliated hospital of Anhui medical university | Hefei, China | Recruiting |
| The affiliated Kangning Hospital of Ningbo University | Ningbo, China | Recruiting |
| Suzhou Guangji Hospital | Suzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07193901